BCL2 is often found to be overexpressed in hematological malignancies and we found RNAs involved in the apoptotic pathway to be retained in the nucleus after XPO1 inhibition; thus, the combination of a BCL-family inhibitor and XPO1 inhibitor seemed to be a promising opportunity to further enhance programmed cell death. Here, BCL2 is linked to hematologic disorder.